NDASUBLINGUALFILM
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
KYNMOBI (apomorphine hydrochloride) by Sumitomo Dainippon Pharma is non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine d4 receptor, and moderate affinity for the dopamine d2, d3, and d5, and adrenergic α1d, α2b, α2c receptors. Approved for parkinson's disease. First approved in 2020.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYNMOBI is a sublingual film formulation of apomorphine hydrochloride, a non-ergoline dopamine agonist approved for Parkinson's disease in 2020. It works by stimulating post-synaptic dopamine D2-type receptors in the brain to manage motor symptoms. The sublingual route provides rapid onset suitable for acute 'off' episodes in Parkinson's patients.
$2MPart D
Peak10.0 years to LOEEarly-stage peak-phase product with low current spending (997 claims in 2023) suggests significant growth opportunity for commercial and medical affairs teams to expand market penetration.
Mechanism of Action
non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, and D5, and adrenergic α1D, α2B, α2C receptors. The precise mechanism of action of ONAPGO as a treatment for Parkinson's disease is unknown, although it is…
Indications (1)
Career Relevance
KYNMOBI currently shows minimal job posting activity, reflecting its early peak-phase status and modest market penetration (only $2M in Part D spending in 2023). Roles in commercial, medical affairs, and market access will likely grow as the brand invests in physician education and patient awareness campaigns to capture a larger share of the Parkinson's dopamine agonist market.
Worked on KYNMOBI at Sumitomo Dainippon Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.